☰

Douglas K. Graham

Affiliations: 
2003-2015 Molecular Biology University of Colorado Anschutz Medical Campus, Denver, Aurora, CO 
 2015- Pediatrics Emory University, Atlanta, GA 
Area:
Molecular Biology, Cancer Biology, Pediatric Leukemia, Receptor Tyrosine Kinase
Google:
"Douglas Graham"
Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor

Children

Sign in to add trainee
Sufit, A grad student University of Colorado, Denver
Christopher Cummings grad student University of Colorado, Denver
Kristen Jacobsen grad student University of Colorado, Denver
Justine C. Migdall-Wilson grad student 2012 University of Colorado, Denver
Jennifer Schlegel grad student 2012 University of Colorado, Denver

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

DeRyckere D, Huelse JM, Earp HS, et al. (2023) TAM family kinases as therapeutic targets at the interface of cancer and immunity. Nature Reviews. Clinical Oncology
Kelvin JM, Chimenti ML, Zhang DY, et al. (2023) Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia. Journal of Controlled Release : Official Journal of the Controlled Release Society
Summers RJ, Jain J, Vasileiadi E, et al. (2022) Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia. Cancers. 14
Yan D, Huelse JM, Kireev D, et al. (2022) MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. The Journal of Clinical Investigation
Yan D, Earp HS, DeRyckere D, et al. (2021) Targeting MERTK and AXL in Mutant Non-Small Cell Lung Cancer. Cancers. 13
Zheng H, Zhao J, Li B, et al. (2021) UNC5293, a potent, orally available and highly MERTK-selective inhibitor. European Journal of Medicinal Chemistry. 220: 113534
Huelse JM, Fridlyand DM, Earp S, et al. (2021) Corrigendum to "MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system" [Pharmacology & Therapeutics 213 (2020) 107577]. Pharmacology & Therapeutics. 107822
Lee-Sherick AB, Jacobsen KM, Henry CJ, et al. (2020) MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. Jci Insight. 5
Huelse J, Fridlyand D, Earp S, et al. (2020) MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. Pharmacology & Therapeutics. 107577
Yan D, Huelse J, Parker R, et al. (2020) Abstract 1882: MERTK drives residual tumor growth in EGFR-mutated non-small cell lung cancer cells treated with osimertinib Cancer Research. 80: 1882-1882
See more...